In the recent study of Shi et al, the third-generation EGFR inhibitor of osimertinib, selectively and irreversibly inhibits EGFR activating and T790 M mutants, could enhance apoptosis induced by TRAIL primarily in NSCLC with activating EGFR mutations [15]. Here, EGFR is linked to non-small cell lung carcinoma.